Medicines Co. Aktie
Finanztrends
Deine Einschätzung
Was spricht für und gegen Medicines Co. in den nächsten Jahren?
Pro
?
M************
?
A****************
?
M****
Kontra
?
U****************
?
L*********** I********** f** d** n******* J****
?
W******* i* V********
Sag uns deine Meinung, um die 'Wisdom of the Crowds' zu nutzen
Rendite von Medicines Co. im Vergleich
| Wertpapier | Ver.(%) | 1W | 1M | 1J | YTD | 3J | 5J |
|---|---|---|---|---|---|---|---|
| Medicines Co. | - | - | - | - | - | - | - |
| Repligen Corp. | -1,22 % | -2,63 % | -3,86 % | -0,08 % | -29,39 % | -33,16 % | -41,97 % |
| Opko Health Inc. | 3,09 % | 6,60 % | 1,98 % | -23,77 % | -8,27 % | -21,16 % | -71,37 % |
| Amicus Therapeutics Inc. | -2,51 % | 0,16 % | 0,16 % | 103,67 % | 1,83 % | 20,99 % | 58,70 % |
Kommentare
News
Is Relay Therapeutics a Buy in 2026? One Institutional Investor Just Made a $6 Million Bet.
According to a Securities and Exchange Commission (SEC) filing dated Feb. 17, 2026, Nextech Invest, Ltd. bought 855,097 additional shares of Relay Therapeutics (NASDAQ:RLAY). The estimated
Biotech Stock Still Up 700% Despite 30% Drop This Year as One Fund Discloses $9 Million Exit
On February 17, 2026, 5AM Venture Management reported selling its entire stake in Praxis Precision Medicines (NASDAQ:PRAX), an estimated $9.01 million trade based on last-disclosed position values.
This Biotech Stock Up 700% Is Still a Top Holding Despite a $9.3 Million Sale Last Quarter
Cormorant Asset Management disclosed a sale of 50,000 shares of Praxis Precision Medicines (NASDAQ:PRAX) in a February 17, 2026, SEC filing, with an estimated transaction value of $9.31 million